FDA has approved Takeda‘s Uloric (febuxostat), indicated for the chronic management of hyperuricemia in patients with gout. The once-daily product represents the first new treatment option in more than 40 years, according to a company release.
Device manufacturer C.R. Bard announced an FDA pre-market approval for its LifeStent FlexStar and FlexStar XL Vascular Stent Systems. The devices are approved for the treatment of occlusive disease in native superficial femoral arteries and proximal popliteal arteries, and are marketed by Bard’s peripheral vascular division, in Tempe, AZ.
